Theravance Biopharma Inc (TBPH)
9.54
-0.14
(-1.45%)
USD |
NASDAQ |
Apr 17, 16:00
9.54
0.00 (0.00%)
After-Hours: 19:29
Theravance Biopharma Cash from Investing (TTM): -32.70M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -32.70M |
September 30, 2023 | 7.141M |
June 30, 2023 | 1.083B |
March 31, 2023 | 1.079B |
December 31, 2022 | 1.154B |
September 30, 2022 | 1.126B |
June 30, 2022 | 14.47M |
March 31, 2022 | 42.72M |
December 31, 2021 | 124.49M |
September 30, 2021 | 166.04M |
June 30, 2021 | 268.37M |
March 31, 2021 | 56.02M |
December 31, 2020 | 10.72M |
September 30, 2020 | -27.59M |
June 30, 2020 | -117.78M |
March 31, 2020 | 57.51M |
December 31, 2019 | -83.05M |
September 30, 2019 | 2.281M |
June 30, 2019 | 72.58M |
March 31, 2019 | 115.84M |
December 31, 2018 | 176.71M |
Date | Value |
---|---|
September 30, 2018 | 118.56M |
June 30, 2018 | 86.68M |
March 31, 2018 | 55.90M |
December 31, 2017 | -56.33M |
September 30, 2017 | -143.79M |
June 30, 2017 | -208.39M |
March 31, 2017 | -288.14M |
December 31, 2016 | -148.24M |
September 30, 2016 | -136.53M |
June 30, 2016 | -24.60M |
March 31, 2016 | 85.27M |
December 31, 2015 | 111.04M |
September 30, 2015 | 155.23M |
June 30, 2015 | -16.72M |
March 31, 2015 | -62.48M |
December 31, 2014 | -106.25M |
September 30, 2014 | -117.00M |
June 30, 2014 | -7.382M |
March 31, 2014 | -3.614M |
December 31, 2013 | -2.634M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-117.78M
Minimum
Jun 2020
1.154B
Maximum
Dec 2022
263.29M
Average
56.02M
Median
Mar 2021
Cash from Investing (TTM) Benchmarks
Corcept Therapeutics Inc | 90.91M |
Nektar Therapeutics | 139.56M |
Vanda Pharmaceuticals Inc | -12.06M |
Fate Therapeutics Inc | 112.66M |
FibroGen Inc | 153.66M |